Delivery Order SPE2DB20D3303-SPE2DB25FA1EY
- Not listed
- The Defense Logistics Agency awarded a $7,142.54 delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Contrave ER 8-90 mg tablets (120 count). This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 25, 2025. This delivery order is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,515.09 delivery order for Contrave ER 8-90 mg tablets (120-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $1,061.90 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Contrave ER 8-90 mg tablets (120-unit quantity). This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a $5,214.68 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Contrave ER 8-90 mg tablets (120-count units). This is a firm fixed-price, non-competitive award with an ultimate completion date of September 23, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen Drug Corp maintains its corporate headquarters. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Contrave ER 8-90 mg tablets (120-count units) valued at $7,553.07 under a firm fixed-price contract. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Contrave ER 8-90 mg tablets (120-count units) valued at $2,449.83 with a completion date of August 1, 2025. This competitive award, issued without set-aside designation, represents a firm fixed-price delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The contract will be performed at the vendor's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $1,352.44 to AmerisourceBergen Drug Corp for the supply of Contrave ER 8-90 mg tablets (120 count) on September 11, 2025, with completion expected by September 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Contrave ER 8-90 mg tablets (120-count units) valued at $2,585.52. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 19, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting the company's competitive standing in federal...
- The Defense Logistics Agency awarded a delivery order valued at $3,012.78 to AmerisourceBergen Drug Corp for the supply of Contrave ER 8-90 mg tablets (120 count) on September 26, 2025, with completion scheduled for September 29, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a $4,829.52 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Contrave ER 8-90 mg tablets (120-count units). This contract represents a firm fixed-price delivery order with no set-aside designation, executed through competitive procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order carries an ultimate completion date...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA1EYDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,092.36 to AmerisourceBergen Drug Corp for the supply of Contrave ER 8-90 mg tablets (120-count) on July 9, 2025, with completion expected by July 10, 2025. This firm fixed price, competitively awarded contract (no set-aside designation) is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a delivery order under a larger indefinite delivery contract vehicle established between DLA and the vendor. This delivery order falls under AmerisourceBergen Drug Corp's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a broad range of pharmaceutical products, medical devices, and healthcare commodities to support military and veteran healthcare systems. The company's selection for this contract reflects its demonstrated capability to meet federal procurement requirements and support the Defense Health Agency and other government healthcare systems with reliable pharmaceutical supply chain solutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/9/25 |